Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
The Curators of the University of Missouri Patents
Assignee:
The Curators of the University of Missouri
Address:
Columbia, MO
No. of patents:
332
Patents:


1 2 3 4 5 6 7










Patent Number Title Of Patent Date Issued
6784341 Defense-related signaling genes and methods of use August 31, 2004
The invention provides isolated SNAP25 nucleic acids, their encoded proteins, and a loss-of-function phenotype of the SNAP25 gene. The present invention provides methods and compositions relating to altering SNAP25 concentration and/or composition of plants. The invention further provide
6780882 Substituted benzimidazole dosage forms and method of using same August 24, 2004
There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazol
6773917 Use of DNA encoding plastid pyruvate dehydrogenase and branched chain oxoacid dehydrogenase comp August 10, 2004
Provided are nucleic acid coding sequences and methods utilizing these sequences for optimizing levels of substrates employed in the biosynthesis of copolymers of 3-hydroxybutyrate (3HB) and 3-hydroxy-valerate (3HV) in plants via manipulation of normal metabolic pathways using recombinan
6750380 Isolated nucleic acid moelcules encoding the Dw3 P-glycoprotein of sorghum and methods of modify June 15, 2004
The invention relates to the genetic modification of plants particularly to the expression of P-glycoprotein genes in transformed plants. Nucleotide sequences for Dw3 genes encoding a P-glycoprotein of sorghum, and method for their use are provided. The sequences fine use in modifying th
6746843 Methods of screening novel agents for use in cancer therapy and prevention June 8, 2004
The present invention provides for methods of screening agents for cancer therapeutic and prophylactic activity. In particular embodiments, cells of the cellular slime mold Dictyostelium discoideum are contacted with candidate agents and the expression of genes in the Nucleotide Excision
6741348 Ultrasensitive spectrophotometer May 25, 2004
The invention concerns improvements in spectrophotometry. Aspects of the invention may be used independently or together to increase the sensitivity of spectrophotometry. One aspect of the invention is a spectrophotometer detection circuit. In this aspect of the invention, currents a
6738664 Method of and apparatus for atrial and ventricular defibrillation or cardioversion with an elect May 18, 2004
An apparatus having a discharging energy source, two electrodes adapted to make electrical contact with a patient, a connecting mechanism forming an electrical circuit between the energy source and the electrodes and a controller operating the connecting mechanism. The apparatus delivers
6714149 Electro-optical analog to digital conversion method and device March 30, 2004
In the invention, an analog signal is converted to an optical deflection. In preferred embodiments, an N-bit parallel output is obtained. A particularly preferred embodiment patterns the light beam with a spatial filter into an N-bit binary light pattern that is then collected and se
6712916 Metal superplasticity enhancement and forming process March 30, 2004
A shaped metallic component is formed by friction stirring at least a segment of a single piece of bulk metal to impart superplasticity thereto and thereby yield a single superplastic metal blank from the single piece of bulk metal. The metal blank is then deformed by a metal deformation
6709744 Bioactive materials March 23, 2004
Bioactive substantially silica-free glass material with a hydroxyapatite layer thereon is described, as well as methods for producing hydroxyapatite on a borate glass.
6699885 Substituted benzimidazole dosage forms and methods of using same March 2, 2004
Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
6696775 Apparatus for commutation of a helical coil launcher February 24, 2004
Apparatus for commutating turns of a stator coil for a helical coil launcher. An annular brush assembly includes an annular support and a plurality of electrical contacts disposed circumferentially about the annular support for contacting the stator coil. A projectile for a helical c
6680045 Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma January 20, 2004
A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount
6665468 Focal plane array optical data extraction and memory December 16, 2003
The charge of pixels in a FPA array is retrieved by propagating an optical wave through a waveguide to interact with pixel charges from the FPA. An optical detector receives an optical wave altered by the respective pixel charges as it travels. The optical wave is sensed after passing th
6664408 Process for preparing organically-substituted polyoxometalates December 16, 2003
The present invention is generally directed to a process for preparing polyoxometalates having amine-derived substituents attached thereto. In a first embodiment, the process comprises contacting a polyoxometalate and an amine in the presence of a diimide. The present invention is furthe
6635235 Bifunctional chelating agent for the design and development of site specific radiopharmaceutical October 21, 2003
There is provided a method of labeling a biomolecule with a transition metal or radiometal in a site specific manner to produce a diagnostic or therapeutic pharmaceutical compound by synthesizing a P.sub.2 N.sub.2 -bifunctional chelating agent intermediate, complexing the intermediate
6630339 Glycine and phaseolus .alpha.-D-galactosidases October 7, 2003
A DNA (SEQ ID No.:2) and amino acid (SEQ ID No.:4) sequences of Glycine .alpha.-D-galactosidase are provided as well as the DNA sequence (SEQ ID No:5) and mature length amino acid sequence (SEQ ID No:7) of Phaseolus.
6617497 Cytokinin oxidase September 9, 2003
An isolated protein which exhibits cytokinin oxidizing activity selected from the group consisting of SEQ. ID No. 1, a protein having an amino acid sequence which includes the amino acid sequence of SEQ. ID No. 1, a protein having an amino acid sequence which includes a portion of the
6610141 Zinc oxide films containing p-type dopant and process for preparing same August 26, 2003
A p-type oxide film and a process for preparing the film and p-n or n-p junctions is disclosed. In a preferred embodiment, a p-type zinc oxide film contains arsenic and is grown on a gallium arsenide substrate. The p-type oxide film has a net acceptor concentration of at least about
6607709 Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma August 19, 2003
A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount
6583217 Composite material composed of fly ash and waste polyethylene terephthalate June 24, 2003
A composite material and method are described wherein melted waste, chemically unmodified PET material and fly ash particles are mixed in a vessel to disperse fly ash particles in the melted PET material. The resulting mixture then is cooled to solidify the melted PET material to for
6531277 Endometriosis-specific secretory protein March 11, 2003
A method and kit of diagnosing endometriosis in a female patient suspected of having endometriosis is disclosed. The method includes obtaining a sample from the patient. The sample is analyzed to detect the presence of ENDO -I glycoprotein or its mRNA in the sample compared to non-en
6495669 Formation of nanometer-scale structures December 17, 2002
Amphiphilic, polyhedron-shaped p-sulfonatocalix[4]arene building blocks, which have been shown previously to assemble into bilayers in an antiparallel fashion, assemble in a parallel alignment into spherical and helical tubular structures on the addition of pyridine N-oxide and lanth
6489346 Substituted benzimidazole dosage forms and method of using same December 3, 2002
There is provided a solid pharmaceutical composition in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomepraz
6475825 Process for preparing zinc oxide films containing p-type dopant November 5, 2002
A p-type zinc oxide film and a process for preparing the film is disclosed. In a preferred embodiment, the p-type zinc oxide film contains arsenic and is grown on a gallium arsenide substrate. The p-type zinc oxide film has a net acceptor concentration of at least about 10.sup.15 accepto
6410162 Zinc oxide films containing P-type dopant and process for preparing same June 25, 2002
A p-type zinc oxide film and a process for preparing the film and p-n or n-p junctions is disclosed. In a preferred embodiment, the p-type zinc oxide film contains arsenic and is grown on a gallium arsenide substrate. The p-type zinc oxide film has a net acceptor concentration of at leas
6399749 .alpha.-N-acetylgalactosaminidase from Clostridium perfringens June 4, 2002
An isolated and purified .alpha.-N-acetyl-D-galactosaminidase from Clostridium perfringens is disclosed. A method for purifying and isolating the .alpha.-N-acetylgalactosaminidase from Clostridium perfringens by removing neuramidases is disclosed. A process for using the .alpha.-N-ac
6379648 Biodegradable glass compositions and methods for radiation therapy April 30, 2002
A nonradioactive glass in particulate form adapted for radiation therapy in a mammal comprise a biodegradable rare earth-lithium borate glass material of a specified composition which, upon being subjected to an effective amount of neutron irradiation, will produce a beta or gamma emitti
6375690 Process for forming coal compacts and product thereof April 23, 2002
A process for forming durable, mechanically strong compacts from coal particulates without use of a binder is disclosed. The process involves applying a compressive stress to a particulate feed comprising substantially water-saturated coal particles while the feed is heated to a fina
6372436 Method for construction of cDNA libraries enriched in clones corresponding to rare mRNA April 16, 2002
The present invention provides for a method for producing a cDNA library enriched for rare cDNAs and reduced in abundant cDNAs which comprises: (a) obtaining a pool of linear double-stranded cDNAs; (b) cloning a first portion of the pool of cDNAs into a first vector to create a first cDN
6358531 Method for preparing porous shells or gels from glass particles March 19, 2002
A method is provided for preparing shells, concentric shells or porous, homogenous gels from alkali borate glass particles at low temperatures (i.e. room temperature or less than above 100.degree. C.). The alkali borate glass particles contain one or more cations such as aluminum which
6342313 Oxide films and process for preparing same January 29, 2002
A p-type oxide film and a process for preparing the film and p-n or n-p junctions is disclosed. In a preferred embodiment, a p-type zinc oxide film contains arsenic and is grown on a gallium arsenide substrate. The p-type oxide film has a net acceptor concentration of at least about
6342181 Corrosion resistant nickel-based alloy January 29, 2002
A nickel based, high silicon alloy exhibits very high corrosion resistance in high temperature sulfuric acid environments. The alloy may be cast and is sufficiently ductile to be fabricated and machined. The alloy is ductile and has sufficient resistance to mechanical and thermal shock t
6338834 Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma January 15, 2002
A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount
6326042 Antimicrobial use of heat-treated lactic and/or glycolic acid compositions for treatment of grou December 4, 2001
Heat-treated lactic and/or glycolic acid compositions are provided herein which are useful for antimicrobial treatment of surfaces, preferably food surfaces including fruits, vegetables and animal carcasses and of particulate materials, preferably ground meats, or other materials into
6309843 Glycoprotein for use in determining endometrial receptivity October 30, 2001
An isolated and purified glycoprotein designated PUP-1 and functional analogs thereof are disclosed and characterized by being a progesterone induced and estradiol inhibited secretory glycoprotein from stromal cells of endometrial origin; having an N-terminal amino acid sequence as set
6303270 Highly plasma etch-resistant photoresist composition containing a photosensitive polymeric titan October 16, 2001
A composition is derived from an addition polymerizable organotitanium polymer which upon exposure to an oxygen plasma or baking in air, is converted to titanium dioxide (titania) or is converted to a mixed, titanium-containing metal oxide. The metal oxide formed in situ imparts etch
6291085 Zinc oxide films containing P-type dopant and process for preparing same September 18, 2001
A p-type zinc oxide film and a process for preparing the film is disclosed. In a preferred embodiment, the p-type zinc oxide film contains arsenic and is grown on a gallium arsenide substrate. The p-type zinc oxide film has a net acceptor concentration of at least about 10.sup.15 accepto
6229066 Cytokinin oxidase May 8, 2001
An isolated protein which exhibits cytokinin oxidizing activity selected from the group consisting of SEQ. ID No. 1, a protein having an amino acid sequence which includes the amino acid sequence of SEQ. ID No. 1, a protein having an amino acid sequence which includes a portion of the
6222896 Production of 186Re, 188Re and other radionuclides via inorganic Szilard-Chalmers process April 24, 2001
Methods for the production of radionuclides suitable for use in radiopharmaceuticals for diagnostic and therapeutic applications, and specifically, to the production of .sup.186 Re, .sup.188 Re and other radionuclides such as .sup.195m Pt and .sup.198 Au using an inorganic Szilard-Ch
6211440 Hm2 cDNA from maize encoding disease resistance polypeptide April 3, 2001
The invention provides isolated Hm2 nucleic acids. The invention further provides expression cassettes, transferred host cells, and transgenic plants. Also, the invention provides methods of imparting disease resistance to plants susceptible to fungal pathogens, which utilize cyclic
6211429 Complete oocyte activation using an oocyte-modifying agent and a reducing agent April 3, 2001
Provided is a method of parthenogenetically activating an unfertilized mammalian oocyte, comprising contacting an unfertilized mammalian oocyte with an oocyte-modifying agent followed by a reducing agent, wherein the mammalian oocyte is in contact with the oocyte-modifying agent and
6200546 Gastrin receptor-avid peptide conjugates March 13, 2001
A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease
6184017 Glycine and phaseolus .alpha.-D-galactosidases February 6, 2001
A DNA (SEQ ID No.:2) and amino acid (SEQ ID No.:4) sequences of Glycine .alpha.-D-galactosidase are provided as well as the DNA sequence (SEQ ID No:5) and mature length amino acid sequence (SEQ ID No:7) of Phaseolus.
6150347 Use of aldosterone antagonists to inhibit myocardial fibrosis November 21, 2000
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
6143561 DNA encoding plastid pyruvate dehydrogenase and branched chain oxoacid dehydrogenase components November 7, 2000
Provided are nucleic acid sequences encoding E1.alpha., E1.beta., and E2 subunits of plastid pyruvate dehydrogenase complexes and branched chain oxoacid dehydrogenase complexes.
6093708 Use of aldosterone antagonists to inhibit myocardial fibrosis July 25, 2000
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
6068428 Capsule train separation system for fluid capsule pipeline transporation May 30, 2000
Apparatus for spacing consecutive capsules of solid material traveling as a capsule train in a pipeline in which the capsules are carried by a fluid flowing through the pipeline includes a separation system interposed between upstream and downstream portions of the pipeline for receiving
6054115 Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and meth April 25, 2000
A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises at least one functionalized hydroxyalkyl phosphine donor group and one or more sulfur or nitrogen donor and a metal combined with the ligand.
6022940 Polymeric compositions and composites prepared from spiroorthocarbonates and epoxy monomers February 8, 2000
Copolymer compositions are provided, including those which undergo less than .+-.1.0% bulk polymerization shrinkage and are useful as strain-free composites, high-strength adhesives, and precision castings. The copolymer compositions are formed from the cationic initiated polymerization
1 2 3 4 5 6 7

 
 
  Recently Added Patents
Method and apparatus for providing auto-completion of information
Image processing apparatus, image processing system, and image processing method
Modulators of cystic fibrosis transmembrane conductance regulator
Printing apparatus having extendable functionality and method thereof
Washing machine
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
Sealed, waterproof digital electronic camera system and method of fabricating same
  Randomly Featured Patents
High pressure hydraulic systems
Bypass engine with means for limiting gas leakage
Personal entertainment device
Photoconductor for electrophotography comprising squarylium containing generator layer and hydrazone containing transport layer
High speed laser marking system
Method and system to improve decision-driven control loops
Cycloidal VTOL UAV
Material handling vehicle
Shielded vent port
Vehicle lamp